CDK4/6 inhibitors versus weekly paclitaxel for ER+/HER2- advanced breast cancer with impending or established visceral crisis

ER+/HER2- advanced breast cancer (ABC) with established visceral crisis (VC) or impending VC (IVC) is commonly treated with chemotherapy instead of CDK4/6 inhibitor. However, there is little evidence to confirm which treatment is superior. A retrospective study at The Christie NHS Foundation Trust (Manchester, UK) compared outcomes of patients with ER+/HER2- ABC and IVC/VC treated with CDK4/6 inhibitors or weekly paclitaxel. Patients receiving CDK4/6 inhibitors had superior outcomes compared with patients receiving chemotherapy. The authors conclude that prospective studies that minimize possible selection bias are warranted.